Ligand Pharmaceuticals Incorporated (LGND)
The company now
Ligand Pharmaceuticals Incorporated is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in San Diego, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $268 million and a profit of $124 million (its filed statements).
From its filings and filed figures; the desk's account of it is not written yet.
Where the revenue comes from
fiscal 2025, as filedRevenue by product, fiscal 2025
| Product | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| Material Sales Captisol | $40.2M | $30.9M | 15.1% |
| Material Sales Captisol Core | $40.2M | $30.9M | 15.1% |
| Royalty Kyprolis | $35.5M | $38.4M | 13.3% |
| Filspari | $32.0M | $12.2M | 12.0% |
| Financial Royalty Assets | $28.5M | $13.4M | 10.7% |
| QARZIBA | $23.7M | $11.1M | 8.9% |
| Royalty Rylaze | $13.3M | $13.7M | 5.0% |
| Royalty Other | $10.4M | $7.5M | 3.9% |
| Capvaxive | $10.1M | $626,000 | 3.8% |
| Ohtuvayre | $9.8M | $833,000 | 3.7% |
| Royalty Teriparatide Injection | $8.1M | $8.2M | 3.1% |
| Vaxneuvance | $7.4M | $5.2M | 2.8% |
| License Fees | $7.0M | $1.9M | 2.6% |
As tagged in its annual report (Form 10-K, filed Feb 27, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.
The desk's written account of this company, its Past, Present and Future, is not on file yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
The desk has not written this company's report yet.